RO 7875913
Alternative Names: RO-7875913Latest Information Update: 27 Jan 2026
At a glance
- Originator Genentech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Jan 2026 Preclinical trials in Unspecified (In volunteers) in USA (unspecified route) prior to January 2026
- 15 Jan 2026 Genentech plans a phase I trial for unknown indication (In volunteers) in March 2026 (NCT07342114)